Blog

Axsome Therapeutics stock price rallied this week after the announcement that it had settled its patent lawsuit against Teva.  Sell-side analysts have raised the stock target now that Auvelity’s generic threat has been eliminated.  Under the terms of the settlement, Teva will not enter the market until 2038 or 2039.  Even if other generics emerge, Axsome is likely hampered from offering an earlier date.  This could make Axsome an attractive acquisition target, similar to how Intra-Cellular was recently acquired shortly after settling with a generic for its drug, Capylta.  How did Axsome accomplish such a favorable settlement?  What was Axsome’s patent strategy for Auvelity.